E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Respiratory syncytial virus infection |
|
E.1.1.1 | Medical condition in easily understood language |
Respiratory virus infection |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10061603 |
E.1.2 | Term | Respiratory syncytial virus infection |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine in hospitalized infants and children who are infected with RSV the dose-response relationship of multiple regimens of lumicitabine on antiviral activity based on nasal RSV shedding using qRT-PCR. |
|
E.2.2 | Secondary objectives of the trial |
To determine in hospitalized infants and children who are infected with RSV:
• The safety and tolerability of lumicitabine.
• The PK of JNJ-63549109 in whole blood.
• The impact of lumicitabine on the clinical course of RSV infection.
• The impact of lumicitabine on the duration and severity of signs and symptoms of RSV infection as assessed by the Pediatric RSV Electronic Severity and Outcome Rating System (PRESORS) questionnaire completed by the clinician in the electronic clinical outcome assessment (eCOA) device.
• The impact of lumicitabine on the time to undetectable nasal RSV viral load.
• The impact of lumicitabine on the emergence of RSV strains with resistance-associated mutations.
• The relationship between the PK of JNJ-63549109 and the PD (antiviral activity, clinical symptoms, and selected safety parameters) after single (LD) and repeated oral dosing (MD) of lumicitabine.
• The acceptability and palatability of the lumicitabine formulation. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Male or female infants and children ≥28 days to ≤36 months of age, defined at the time of randomization.
• Subjects hospitalized (or in ER) at the time of randomization and unlikely to be discharged for the first 24 hours after randomization.
• Subjects diagnosed with RSV infection using a PCR-based molecular diagnostic assay, with or without coinfection with another respiratory pathogen (respiratory virus or bacteria).
• Subjects who have an acute respiratory illness with signs and symptoms consistent with a viral infection (eg, fever, cough, nasal congestion, runny nose, sore throat, myalgia, lethargy, shortness of breath, or wheezing) with onset ≤5 days from the anticipated time of randomization.
• With the exception of the symptoms related to the RSV infection or defined comorbid condition for severe RSV disease (prematurity at birth [subject’s gestational age was <37 weeks; for infants <1 year old at randomization], bronchopulmonary dysplasia,congenital heart disease, other congenital diseases, Down syndrome, neuromuscular impairment, or cystic fibrosis), subjects must be medically stable on the basis of physical examination, medical history, vital signs/SpO2, and ECG performed at screening.
• The subject’s estimated glomerular filtration rate (eGFR) is not below the lower limit of normal for the subject’s age (Schwartz equation calculation). |
|
E.4 | Principal exclusion criteria |
• Subjects who are not expected to survive for more than 48 hours.
• Subjects who have had major thoracic or abdominal surgery in the 6 weeks prior to randomization.
• Subjects who received (within 12 months prior to screening) or who are currently on a waiting list for a bone marrow, stem cell, or solid organ transplant, who received radiation or chemotherapy, or who are currently taking immunosuppressive medication.
• Subjects who have a known or suspected immunodeficiency (except immunoglobulin A [IgA] deficiency), such as a known human immunodeficiency virus infection.
• Subjects who have a history of or concurrent illness (beyond a defined comorbid condition for severe RSV disease) that in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject, or that could prevent, limit, or confound the protocol-specified assessments.
• Subjects aged ≥28 days to 35 days with <8.0 g/dL (Grade 3) hemoglobin or a cardiac failure secondary to anemia (Grade 4) and subjects aged ≥36 days to 36 months with <7.0 g/dL (Grade 3) hemoglobin or cardiac failure secondary to anemia (Grade 4).
• Subjects aged ≥28 days to 60 days with <899/mm3 absolute neutrophil count) and subjects aged ≥61 days to ≤36 months with <399/mm3 absolute neutrophil count.
• Subjects aged ≥28 days to ≤36 months with <49,999/mm3 platelet count (Grade 3/4). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint in this study is RSV RNA log10 viral load (measured by qRT-PCR assay in the mid-turbinate nasal swab specimens) AUC immediately prior to first dose of study drug (baseline) over 7 days. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Samples for the determination of RSV viral load will be taken as close as possible and before the LD on Day 1 and once daily at approximately the same time each day prior to study drug administration between Day 2 and Day 6 (whether hospitalized or not), and at the Day 7, Day 10, Day 14, and Day 28 visits. |
|
E.5.2 | Secondary end point(s) |
• Safety/tolerability including adverse events (AEs), physical examinations, vital signs/peripheral capillary oxygen saturation (SpO2), electrocardiogram (ECG), and clinical laboratory results.
• PK parameters of JNJ-63549109.
• RSV clinical course endpoints:
o Length of hospital stay from admission to discharge and to readiness for discharge and from study treatment initiation to discharge and to readiness for discharge, with readiness for discharge evaluated by the investigator.
o Requirement for and duration of intensive care unit (ICU) stay.
o Requirement for and duration of oxygen supplementation/noninvasive mechanical ventilation support and/or invasive mechanical ventilation support above pre-RSV infection status.
o Time to no longer requiring supplemental oxygen above pre-RSV infection status.
o Time to clinical stability defined as the time from initiation of study treatment until the time at which the following criteria are met: return to pre-RSV infection status (hereafter referred to as “normalization”) of blood oxygen level (ie, without additional requirement of supplemental oxygen compared with pre-RSV infection status), normalization of oral feeding, normalization of respiratory rate, and normalization of heart rate.
o Time from initiation of study treatment until SpO2 ≥93% on room air among subjects who were not on supplemental oxygen prior to the onset of respiratory symptoms.
o Time to respiratory rate, SpO2, and body temperature return to pre-RSV infection status.
o Incidence of acute otitis media (defined by the investigator).
• The duration and severity of signs and symptoms of RSV infection as assessed by the PRESORS questionnaire completed by the clinician in the eCOA device.
• RSV viral load as measured by qRT-PCR in the mid-turbinate nasal swab specimens, which will be used to determine the following:
o RSV viral load over time.
o Peak viral load, time to peak viral load, rate of decline of viral load, and time to RSV RNA being undetectable.
o Proportion of subjects with undetectable RSV viral load at each timepoint.
o RSV viral load AUC from immediately prior to first dose of study drug (baseline) until Day 10 and until Day 14.
o RSV viral load AUC in subjects assigned to a longer dosing duration, if dosing duration is increased by the IDMC, from baseline until 1 day (+2 days) after the last dose of study drug.
• Sequence changes (postbaseline) in the RSV polymerase L-gene and other regions (if warranted) of the RSV genome compared with baseline sequences.
• Acceptability and palatability of the lumicitabine formulation as assessed by the parent(s)/caregiver(s) eCOA. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Safety and tolerability: evaluated throughout the study.
PK sampling: Post Dose 1 (0.25-2h), Post Dose 2 (0.5-1h OR 7h) and Day 7 visit.
Clinical evaluation and clinician eCOA: Screening and twice daily for the
entire duration of hospitalization. After hospital discharge: at the Day 7, Day 10, Day 14, and Day 28 visits.
Nasal swabs [RSV viral load and viral resistance (genome sequencing)]: before the LD on Day 1, once daily prior to study drug administration between Day 2 and Day 6 (whether hospitalized or not), and at the Day 7, Day 10, Day 14, and Day 28 visits.
Parent(s)/caregiver(s) eCOA: Screening and twice daily for the entire duration of hospitalization. After hospital discharge: twice daily until the Day 14 visit, and once daily up to the Day 28 visit. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 69 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Austria |
Belgium |
Brazil |
Canada |
Chile |
Colombia |
Czech Republic |
Finland |
France |
Germany |
Hungary |
Ireland |
Israel |
Italy |
Japan |
Korea, Republic of |
Malaysia |
Netherlands |
New Zealand |
Panama |
Poland |
Portugal |
Slovakia |
Spain |
Sweden |
Taiwan |
Thailand |
Ukraine |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 12 |